Brief: Protagonist Therapeutics Announces Positive Topline Results For Phase 2B Frontier 1 Clinical Trial Of Oral Il-23 Receptor Antagonist JNJ-2113 (Pn-235) In Psoriasis

Protagonist Therapeutics

07/03/2023 13:02

March 7 (Reuters) - Protagonist Therapeutics Inc
 PTGX.O :
    * PROTAGONIST THERAPEUTICS ANNOUNCES POSITIVE TOPLINE
RESULTS FOR
PHASE 2B FRONTIER 1 CLINICAL TRIAL OF ORAL IL-23 RECEPTOR
ANTAGONIST JNJ-2113 (PN-235) IN PSORIASIS
    * PROTAGONIST THERAPEUTICS INC - JNJ-2113 (FORMERLY PN-235)
MET
STUDY'S PRIMARY ENDPOINT
    * PROTAGONIST THERAPEUTICS INC - TREATMENT WAS WELL
TOLERATED,
WITH NO MEANINGFUL DIFFERENCE IN FREQUENCY OF ADVERSE EVENTS
ACROSS TREATMENT GROUPS

Source text for Eikon:  ID:nPn1JcXL9a 
Further company coverage:  PTGX.O 

 ((Reuters.Briefs@thomsonreuters.com;))